(VIANEWS) - NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Vivaldi Asset Management, LLC (ADC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
37.6% sales growth and 33.43% return on equity
NVIDIA Corporation operates as a visual computing company worldwide.
NVIDIA's sales growth this year is anticipated to be 48.9% and 9.9% for next year.
Year-on-year quarterly revenue growth grew by 83.8%, now sitting on 19.26B for the twelve trailing months.
Volume
Today's last reported volume for NVIDIA is 20380300 which is 47.4% below its average volume of 38747500.
NVIDIA's sales growth is a negative 0% for the present quarter and 37.6% for the next. The company's growth estimates for the current quarter and the next is 88.1% and 43.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.43%.
Volatility
NVIDIA's last day, last week, and last month's current volatility was 1.42%, 1.16%, and 1.53%, respectively.
NVIDIA's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.83% (day), 2.38% (last week), and 3.24% (last month), respectively.
NVIDIA's Stock Yearly Top and Bottom Value
NVIDIA's stock is valued at $194.58 at 06:22 EST, under its 52-week high of $208.75 and way above its 52-week low of $115.67.
NVIDIA's Moving Average
NVIDIA's value is under its 50-day moving average of $198.07 and way higher than its 200-day moving average of $160.63.Previous days news about NVIDIA(NVDA)
According to Benzinga on Sunday, 15 August, "The CNBCinvestor panel on Friday discussed NVIDIA Corp (NASDAQ: NVDA) ahead of its upcoming earnings report."
According to FXStreet on Tuesday, 17 August, "On top of this tech weakness, one of AMD's chief rivals, NVIDIA (NASDAQ:NVDA) saw its stock fall on the cautious words of a Credit Suisse analyst. ", "Shares of NVIDIA were down as much as 3.6% on Monday, but the stock closed the day 1.18% lower as the markets rallied into the closing bell."
2. Regeneron Pharmaceuticals (REGN)
37.1% sales growth and 33.21% return on equity
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Regeneron Pharmaceuticals's sales growth this year is anticipated to be 42.1% and a negative 6.6% for next year.
Year-on-year quarterly revenue growth grew by 38.3%, now sitting on 9.01B for the twelve trailing months.
Volume
Today's last reported volume for Regeneron Pharmaceuticals is 1180120 which is 60.84% above its average volume of 733692.
Regeneron Pharmaceuticals's sales growth is a negative 0% for the current quarter and 37.1% for the next. The company's growth estimates for the present quarter and the next is 150.3% and 21.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.21%.
Volatility
Regeneron Pharmaceuticals's last day, last week, and last month's current volatility was 2.76%, 0.91%, and 1.05%, respectively.
Regeneron Pharmaceuticals's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.02% (day), 2.42% (last week), and 2.42% (last month), respectively.
Regeneron Pharmaceuticals's Stock Yearly Top and Bottom Value
Regeneron Pharmaceuticals's stock is valued at $647.44 at 06:22 EST, above its 52-week high of $640.65.
Regeneron Pharmaceuticals's Moving Average
Regeneron Pharmaceuticals's worth is way higher than its 50-day moving average of $585.12 and way higher than its 200-day moving average of $515.46.Previous days news about Regeneron Pharmaceuticals(REGN)
According to MarketWatch on Friday, 13 August, "Immunocompromised people likely make up between 3% to 4% of the U.S. population, according to George Yancopoulos, president of Regeneron Pharmaceuticals Inc. REGN, in remarks last week about the company's monoclonal antibody treatment."
According to Benzinga on Friday, 13 August, "eBay Inc (NASDAQ: EBAY), Advanced Micro Devices, Inc. (NASDAQ: AMD) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were among the top gainers for the QQQ."
According to Bloomberg Quint on Monday, 16 August, "Federal and state officials are promoting it, particularly in hard-hit areas, and demand has exploded from a trickle to more than 120,000 doses a week by the latest count from its maker, Regeneron Pharmaceuticals Inc."
According to Benzinga on Tuesday, 17 August, "Moderna Inc (NASDAQ: MRNA), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were among the top gainers for the Nasdaq Tuesday."
3. Vivaldi Asset Management, LLC (ADC)
28.6% sales growth and 3.69% return on equity
Vivaldi Asset Management, LLC's sales growth this year is anticipated to be 35.9% and 22.7% for next year.
Year-on-year quarterly revenue growth grew by 43.5%, now sitting on 295.6M for the twelve trailing months.
Volume
Today's last reported volume for Vivaldi Asset Management, LLC is 337599 which is 45.24% below its average volume of 616609.
Vivaldi Asset Management, LLC's sales growth for the next quarter is 28.6%. The company's growth estimates for the ongoing quarter and the next is 17.9% and 9.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.69%.
Volatility
Vivaldi Asset Management, LLC's last day, last week, and last month's current volatility was 0.15%, 0.63%, and 0.69%, respectively.
Vivaldi Asset Management, LLC's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.02% (day), 1.11% (last week), and 1.36% (last month), respectively.
Vivaldi Asset Management, LLC's Stock Yearly Top and Bottom Value
Vivaldi Asset Management, LLC's stock is valued at $74.39 at 06:22 EST, under its 52-week high of $75.95 and way higher than its 52-week low of $61.27.
Vivaldi Asset Management, LLC's Moving Average
Vivaldi Asset Management, LLC's value is above its 50-day moving average of $73.48 and higher than its 200-day moving average of $69.55.4. AGCO (AGCO)
25.3% sales growth and 17.36% return on equity
AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide.
AGCO's sales growth this year is expected to be 17.2% and 5.3% for next year.
Year-on-year quarterly revenue growth grew by 23.4%, now sitting on 9.6B for the twelve trailing months.
Volume
Today's last reported volume for AGCO is 690905 which is 4.84% above its average volume of 658995.
AGCO's sales growth for the next quarter is 25.3%. The company's growth estimates for the present quarter and the next is 100.9% and 0.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.36%.
Volatility
AGCO's last day, last week, and last month's current volatility was 1.87%, 1.55%, and 1.63%, respectively.
AGCO's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.09% (day), 2.37% (last week), and 2.51% (last month), respectively.
AGCO's Stock Yearly Top and Bottom Value
AGCO's stock is valued at $134.25 at 06:22 EST, way below its 52-week high of $158.62 and way higher than its 52-week low of $69.68.
AGCO's Moving Average
AGCO's value is above its 50-day moving average of $130.08 and below its 200-day moving average of $134.80.5. Select Bancorp (SLCT)
22.8% sales growth and 6.31% return on equity
Select Bancorp, Inc. operates as the bank holding company for Select Bank & Trust Company that provides banking services to individuals and small to medium-sized businesses.
Select Bancorp's sales growth this year is expected to be 19.5% and 0.7% for next year.
Year-on-year quarterly revenue growth grew by 73%, now sitting on 60.08M for the twelve trailing months.
Volume
Today's last reported volume for Select Bancorp is 14241 which is 91.81% below its average volume of 173979.
Select Bancorp's sales growth is a negative 0% for the present quarter and 22.8% for the next. The company's growth estimates for the current quarter and the next is 575% and 85.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.31%.
Volatility
Select Bancorp's last day, last week, and last month's current volatility was 1.48%, 1.46%, and 1.52%, respectively.
Select Bancorp's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.01% (day), 1.98% (last week), and 2.44% (last month), respectively.
Select Bancorp's Stock Yearly Top and Bottom Value
Select Bancorp's stock is valued at $16.93 at 06:22 EST, below its 52-week high of $17.44 and way higher than its 52-week low of $6.93.
Select Bancorp's Moving Average
Select Bancorp's worth is higher than its 50-day moving average of $15.87 and way above its 200-day moving average of $13.33.6. Deere & Company (DE)
19.8% sales growth and 34% return on equity
Deere & Company, together with its subsidiaries, manufactures and distributes various equipment worldwide.
Deere & Company's sales growth this year is expected to be 26.7% and 11.3% for next year.
Year-on-year quarterly revenue growth grew by 30.3%, now sitting on 39.8B for the twelve trailing months.
Volume
Today's last reported volume for Deere & Company is 1206310 which is 30.29% below its average volume of 1730570.
Deere & Company's sales growth is a negative 0% for the current quarter and 19.8% for the next. The company's growth estimates for the current quarter and the next is 75.5% and 66.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34%.
Volatility
Deere & Company's last day, last week, and last month's current volatility was 0.42%, 1.14%, and 1.25%, respectively.
Deere & Company's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.20% (day), 1.92% (last week), and 1.92% (last month), respectively.
Deere & Company's Stock Yearly Top and Bottom Value
Deere & Company's stock is valued at $376.33 at 06:22 EST, below its 52-week high of $400.34 and way higher than its 52-week low of $179.86.
Deere & Company's Moving Average
Deere & Company's value is above its 50-day moving average of $349.59 and above its 200-day moving average of $351.75.7. Barrett Business Services (BBSI)
7.8% sales growth and 20.14% return on equity
Barrett Business Services, Inc. provides business management solutions for small and mid-sized companies in the United States.
Barrett Business Services's sales growth this year is expected to be 5.8% and 7.8% for next year.
Year-on-year quarterly revenue growth grew by 16%, now sitting on 912.34M for the twelve trailing months.
Volume
Today's last reported volume for Barrett Business Services is 10387 which is 56.94% below its average volume of 24125.
Barrett Business Services's sales growth for the next quarter is 7.8%. The company's growth estimates for the current quarter and the next is a negative 0.7% and negative -8.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.14%.
Volatility
Barrett Business Services's last day, last week, and last month's current volatility was 0.59%, 0.88%, and 1.45%, respectively.
Barrett Business Services's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.77% (day), 2.09% (last week), and 2.55% (last month), respectively.
Barrett Business Services's Stock Yearly Top and Bottom Value
Barrett Business Services's stock is valued at $78.39 at 06:22 EST, below its 52-week high of $79.73 and way above its 52-week low of $47.90.
Barrett Business Services's Moving Average
Barrett Business Services's worth is higher than its 50-day moving average of $73.39 and higher than its 200-day moving average of $72.23.8. Globus Medical (GMED)
5.4% sales growth and 8.31% return on equity
Globus Medical, Inc., a medical device company, focuses on the development and commercialization of implants that heal patients with musculoskeletal disorders.
Globus Medical's sales growth this year is anticipated to be 17.5% and 10.1% for next year.
Year-on-year quarterly revenue growth grew by 19.3%, now sitting on 825.81M for the twelve trailing months.
Volume
Today's last reported volume for Globus Medical is 144858 which is 65.68% below its average volume of 422192.
Globus Medical's sales growth for the next quarter is 5.4%. The company's growth estimates for the current quarter and the next is 528.6% and negative -8.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.31%.
Volatility
Globus Medical's last day, last week, and last month's current volatility was 0.17%, 1.31%, and 1.11%, respectively.
Globus Medical's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.55% (day), 2.45% (last week), and 2.02% (last month), respectively.
Globus Medical's Stock Yearly Top and Bottom Value
Globus Medical's stock is valued at $76.64 at 06:22 EST, under its 52-week high of $83.94 and way higher than its 52-week low of $48.00.
Globus Medical's Moving Average
Globus Medical's worth is under its 50-day moving average of $79.91 and higher than its 200-day moving average of $70.29.Previous days news about Globus Medical(GMED)
According to Business Insider on Saturday, 14 August, "(China), Anika Therapeutics Inc. (US), Arthrex Inc. (US), Bioventus LLC (US), Globus Medical Inc. (US), Johnson and Johnson Inc. (US), Medtronic Plc (Ireland), Nuvasive Inc. (US), and Stryker Corp. (US)are some of the dominant players likely to contribute to the significant growth in the market."